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ing beliefs of patients’ reluctance to disclose T&CM usage to healthcare providers
especially the physicians is important especially when they are on active cancer
treatment. Results from this study can help physicians to initiate open discussions
with patients at the time of treatment decision in order to improve patients’ com-
pliance towards proven therapies. Further research is required to evaluate physi-
cians’ attitude towards cancer patients’ use of T&CM.
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OBJECTIVES: Human papillomavirus (HPV) infection is associated with cervical
cancer and genital warts as well as other diseases, such as vulvar, vaginal, anal,
penile and head and neck (H&N) cancers. Utility values for those other cancers will
be needed for more comprehensive cost-effectiveness models of HPV vaccination.
This study aims to identify all utility values for HPV-related cancers in elicitation
and economic evaluation studies. METHODS: Literature searches were imple-
mented using Medline, EMBASE, Tufts University CEA registry, CRD-HTA register
databases and completed with recent conference abstracts. No limits were set on
time, geography or language for searches. All utility elicitation techniques were
considered. RESULTS: 109 abstracts satisfied inclusion criteria: 4 genital warts, 75
cervical, 1 vulvar, 4 anal and 25 H&N cancer abstracts. 19 were excluded after
review of full publications. Most economic evaluations used utilities from previous
models. Two sets of values were identified for cervical cancer: one using time
trade-off (TTO) among healthy female volunteers and another based on expert
opinion. Utilities for H&N cancers were elicited from one study using EQ-5D in
oncology nurses (0.06-0.86 according to treatment status) and one using TTO in 10
physicians (0.68-0.93). Additionally, one study elicited utilities after laryngectomy
from patients and health care providers (0.44-0.89). Utilities for oral cancer were
measured using standard gamble in healthy volunteers (0.68-0.92 by stage). Utili-
ties for anal cancer were based on gastrointestinal cancer. No values were found for
penile, vulvar and vaginal cancers. CONCLUSIONS: Although some data exist for
cervical cancer and genital warts, there is a paucity of high-quality utility data for
other HPV-related diseases. This literature review will be useful for future HPV
economic evaluations. New elicitation studies could be performed to fill in some
gaps. However, for some rare cancers, using other diseases as proxies could be an
acceptable approach.
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OBJECTIVES: Many descriptions of health used in vignettes and condition-specific
measures name the medical condition. This paper assesses the impact of referring
to the medical condition in the descriptions of health states valued by the general
population. METHODS: A valuation study was conducted using face-to-face inter-
views involving the time trade-off valuation technique. All respondents valued the
same eight health states but descriptions featured different labels: no label / “irri-
table bowel syndrome” / “cancer”. We analyse responses from 241 members of the
UK general population providing 1910 observations, with a response rate of 39%
and completion rate of 99%. Random effects generalized least squares regressions
were used to estimate the impact of each label and experience of the condition on
health state values. RESULTS: There is no significant difference between health
state values when the health state description contains no label or an IBS label. The
inclusion of a cancer label in the health state description affects health state values
and the impact is dependent upon the severity of the state, with a significant
reduction in values for more severe health states (up to -0.25 for the worst possible
state) but no significant difference for mild states. CONCLUSIONS: A condition
label can affect health state values, but this is dependent upon the specific condi-
tion and severity. These differences may reflect greater precision for utility esti-
mates experienced for these conditions or preconceptions such as fear and dread.
Further research using qualitative analysis is recommended to enable better un-
derstanding of the reasoning used by respondents to determine why the inclusion
of different condition labels affects health state values. Until this information is
available, we recommend avoiding condition labels in health state descriptions
(where possible) to ensure that values are not affected by prior knowledge or pre-
conception of the condition that may distort the health state being valued.
PCN125
ELICITATION OF HEALTH STATE UTILITIES IN NEUROENDOCRINE TUMOURS
Swinburn P1, Chandiwana D2, Quadri N1, Wang X3, Lloyd AJ1
1Oxford Outcomes, an ICON plc Company, Oxford, Oxon, UK, 2Novartis Pharmaceuticals UK
Limited, Surrey, UK, 3Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA
OBJECTIVES: A number of newly developed treatments for advanced Neuroendo-
crine Tumours (NET) have demonstrated potential for significantly improving out-
comes both in terms of disease progression and tolerability. There is however a
paucity of available evidence detailing the quality of life impact of such therapies
which is suitable for use in supporting economic evaluations. This study was de-
signed to address this unmet need by capturing utility values for receiving NET
treatment. METHODS: A number of health state descriptions were developed to
characterise the typical quality of life challenges faced by NET patients undergoing
therapy. These vignettes were developed based upon the findings of a literature
review, in-depth interviews with patients (n5) and discussions with experienced
NET specialists (clinicians n5, oncology nurse n1). The states described stable
and progressive disease with a range of common treatment related grade III/IV
toxicities (stomatitis, rash, diarrhoea, nausea/vomiting, hyperglycaemia, thrombo-
cytopenia, hand & foot syndrome and pneumonitis). One hundred members of the
UK general public rated each state in a time trade-off (TTO) interview. The TTO
exercise explores participants’ willingness to trade overall survival against
changes in quality of life and therefore provides an indication of its value in that
state. RESULTS: Values suitable for both pancreatic and carcinoid NET treatment
are presented. Stable disease had a reported utility value of 0.77 whilst progressive
disease was associated with a marked decline and a value of 0.62. The impact of
toxicities was variable ranging from stable disease  hyperglycaemia (0.78) to sta-
ble disease stomatitis (0.56).CONCLUSIONS: This study characterises the burden
associated with receiving NET treatment, related adverse events and disease pro-
gression. It demonstrates the considerable value of therapies offering reduced tox-
icity and the prospect of delaying progression in terms of preserving quality of life.
These values could be used in establishing the cost-effectiveness of future treat-
ments.
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OBJECTIVES: Published utilities for the same health condition vary across studies.
The purpose of this study was to find the factors that were related to utilities using
the case of colorectal cancer.METHODS:We did systematic review first to summa-
rize the literature on the utilities of colorectal cancer and ran meta-regression to
analyze the factors affecting the utilities of colorectal cancer. We searched the
literature published up until December, 2010 in Medline, Science Direct, CINAHL,
EMBASE, and KoreaMed using the combinations of keywords, one set of keywords
representing colorectal cancer and the other representing utilities. In total, 88 ab-
stracts were retrieved and 57 were excluded after the abstract review and 15 stud-
ies were excluded after the full-text review. Finally, 228 utility scores in 16 studies
were included in the meta-regression. For each of the 228 utilities, information was
recorded on its cancer stage, cancer type, cancer treatment, adverse reaction, re-
mission, definition of the lower bound, definition of the upper bound, respondent,
preference elicitation method, source of utility, and survey method. Fixed effect
model was used to control for the correlations within the same study. RESULTS:
Compared to stage 1, stage 3, 4, and best supportive care state had lower utilities.
Colorectal cancer had the higher utilities than either colon cancer or rectal cancer.
Adverse reaction was related to lower utilities. Other definition of the upper bound
than perfect health was related to higher utilities. Compared to TTO, HALex had
lower utilities and HUI had higher utilities. On the other hand, the other factors
were not significantly related to the level of utilities. CONCLUSIONS: In the case of
colorectal cancer, utilities were affected by cancer stage, cancer type, adverse re-
action, definition of upper bound, and preference elicitation method. In practice,
we should mind that characteristics of health condition and utility measurement
may affect the level of utilities when we use utilities from the literature.
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OBJECTIVES: 1) To develop both English and Chinese versions of the descriptions of
health states describing different stages of breast cancer and different adverse
effects related to tamoxifen and aromatase inhibitors for breast cancer, and 2) To
elicit individuals’ preferences for these health states from a group of oncology
nurses. METHODS: Twenty hypothetical health states and their descriptions were
developed based on literature review and oncology expert panel reviews. Health
state utilities were obtained from 20 oncology nurses using the visual analogue
scale (VAS) and standard gamble (SG) methods. After recalibration, the adjusted
utility scores were on a scale of 0 (death) and 1 (perfect health). RESULTS: The
health states developed represented different disease stages and the presence and
type of treatment side effects in breast cancer. For each health state, various gen-
eral health-related quality of life domains, such as pain/discomfort and ability to
work, were included in the descriptions, along with a state-specific description.
The mean utility score of respondents’ ‘current health’ was greater than 0.9 while
mean adjusted VAS-derived utility scores ranged from 0.256 to 0.860, and median
adjusted SG-derived utility scores ranged from 0.284 to 0.673. Among the side ef-
fects evaluated in the ‘no recurrence’ health state, ischemic cerebrovascular
events, pulmonary embolism, and spine fracture had the greatest utility detriment.
CONCLUSIONS: The study results indicate the value that individuals place on the
avoidance of disease progression and the side effects of hormonal therapies in
breast cancer. The health state descriptions developed can be used in future re-
search to obtain society’s utilities for use in a cost-utility analysis.
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